Biomea Fusion’s (BMEA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Biomea Fusion (NASDAQ:BMEA) in a research note published on Wednesday,Benzinga reports. They currently have a $12.00 price target on the stock.

BMEA has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biomea Fusion in a research note on Wednesday, January 21st. Rodman & Renshaw began coverage on shares of Biomea Fusion in a report on Tuesday, January 13th. They set a “buy” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Biomea Fusion Price Performance

BMEA stock opened at $1.32 on Wednesday. The firm has a 50 day simple moving average of $1.29 and a two-hundred day simple moving average of $1.42. Biomea Fusion has a one year low of $0.87 and a one year high of $3.08. The stock has a market cap of $95.44 million, a PE ratio of -1.01 and a beta of -0.20.

Hedge Funds Weigh In On Biomea Fusion

Large investors have recently made changes to their positions in the company. Griffin Asset Management Inc. raised its position in Biomea Fusion by 19.5% in the 3rd quarter. Griffin Asset Management Inc. now owns 61,300 shares of the company’s stock valued at $124,000 after purchasing an additional 10,000 shares during the last quarter. Scientech Research LLC purchased a new position in Biomea Fusion in the third quarter worth $25,000. Engineers Gate Manager LP acquired a new stake in Biomea Fusion in the second quarter valued at $26,000. Millennium Management LLC boosted its position in shares of Biomea Fusion by 156.7% during the 4th quarter. Millennium Management LLC now owns 25,677 shares of the company’s stock worth $32,000 after purchasing an additional 15,675 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Biomea Fusion during the 3rd quarter worth $32,000. 96.72% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Biomea Fusion

Here are the key news stories impacting Biomea Fusion this week:

• Positive Sentiment: Citigroup raised its price target on BMEA from $6.00 to $7.00 and reiterated a “buy” rating — the new target implies substantial upside versus the current share level. Read More.
• Positive Sentiment: HC Wainwright published a set of updated EPS forecasts (Q1–Q4 2026 and FY2026–FY2028) and materially lifted its multi-year loss estimates (FY2026 from ($1.37) to ($0.57); FY2027 to ($0.64); FY2028 to ($0.78)), signaling the firm expects smaller losses and improving financials over time. The report also lists per-quarter EPS expectations for 2026. Read More.
• Positive Sentiment: D. Boral Capital initiated/maintained a buy rating on Biomea Fusion, adding another independent positive analyst voice. Read More.
• Positive Sentiment: Recent coverage highlights continued strong analyst sentiment driven by encouraging diabetes trial results, supporting the investment case for BMEA’s pipeline upside. Read More.
• Neutral Sentiment: Despite the positive analyst action and trial commentary, the stock is trading lower today — likely a short-term reaction (profit-taking, low liquidity, or risk-off flows common in small-cap biotech) rather than a reversal of analyst views. Monitor trading volume and upcoming clinical or corporate catalysts for signs of follow-through.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.